Nilomi V. Shah.
Chief of Staff · Lexeo Therapeutics

Nilomi V. Shah, Pharm.D.

Strategy partner to the CEO & Executive Leadership Team at Lexeo Therapeutics, built on over a decade of medical affairs leadership across gene therapy, rare disease, cardiovascular, and hepatology.

New York, NY

View Experience Get in Touch
Portrait of Nilomi V. Shah
About

A pharmaceutical industry leader with a patient-centric focus.

Now Chief of Staff at Lexeo Therapeutics, partnering with the CEO and Executive Leadership Team to shape corporate strategy and drive the company's highest-priority initiatives to advance transformative science for patients.

Built on nearly twelve years of Medical Affairs experience spanning biotech and pharma, with deep expertise across gene therapy, rare disease, neurology, hepatology, and cardiovascular therapeutic areas — covering pediatric and adult medicine, small molecules, and advanced therapies. Known for leading strategic medical initiatives across marketed, launch, and investigational assets, and for building durable partnerships with internal teams and external scientific communities alike.

Therapeutic Areas

Gene Therapy Rare Disease Neurology Hepatology Cardiovascular Pediatrics NASH Oncology
Experience

From medical affairs leadership to the C-suite.

May 2026 – Present

Lexeo Therapeutics

Chief of Staff

Strategy Partner to the CEO & Executive Leadership Team

New York, NY

Corporate Strategy Gene Therapy Cardiovascular Rare Disease

Partnering with the CEO and Executive Leadership Team to shape corporate strategy and drive Lexeo Therapeutics' high-priority initiatives to advance transformative science for patients. Lexeo is a clinical-stage gene therapy biotech developing AAV-based therapies for genetic cardiovascular disease — including Friedreich Ataxia cardiomyopathy and arrhythmogenic cardiomyopathy — and APOE4-associated Alzheimer's disease.

Jan 2022 – May 2026

Lexeo Therapeutics

Executive Director, Medical Affairs

Director → Senior Director → Executive Director, Medical Affairs

New York, NY

Gene Therapy Cardiovascular Rare Disease CNS

Led medical affairs at Lexeo from its early clinical stage through its Nasdaq listing, rising from Director, Medical Affairs Lead to Senior Director and then Executive Director.

Built the medical affairs function across Lexeo's pipeline of high-impact genetic medicines, grounded in translational research from Weill Cornell Medicine and UC San Diego.

Jul 2019 – Jan 2022

Neurogene Inc.

Director, Medical Affairs

New York, NY

Gene Therapy Pediatric Neurology Rare Disease
  • ◆Co-led identification and profiling of 250+ thought leaders in lysosomal storage disorders and leukodystrophy.
  • ◆Planned and executed 3 global advisory boards and roundtables guiding clinical and regulatory decisions.
  • ◆Led global scientific conference strategy and execution across priority congresses.
  • ◆Co-led digital initiative to identify and educate ~2,000 HCP specialists on Batten disease and advance genetic testing.
  • ◆Developed company-wide publication plans mapped to key conferences and communication goals.
  • ◆Medical lead on MLR review committee, ensuring accuracy and lexicon consistency across all materials.

May 2016 – Jul 2019

Intercept Pharmaceuticals

Manager → Senior Manager, Global Medical Affairs

New York, NY

NASH Primary Biliary Cholangitis
  • ◆Developed integrated society engagement plan aligning cross-functional priorities with scientific community needs.
  • ◆Led strategic conference planning and execution across all key hepatology meetings.
  • ◆Managed post-Phase 3 NASH data advisory board with 20 global advisors.
  • ◆Led competitor data analysis from scientific meetings to inform business-critical activities.
  • ◆Point of contact for institutional processes including advisory boards, contracting, and regulatory review.

Jul 2014 – May 2016

Daiichi Sankyo, Inc.

Post-doctoral Fellow, US & Global Medical Affairs

Rutgers 2-Year Fellowship

Parsippany, NJ

Cardiovascular Oncology
  • ◆Led and launched an evolved edoxaban global scientific platform; presented to Global leadership in London.
  • ◆Planned and executed training programs for 100+ attendees across medical, commercial, and field teams.
  • ◆Trained sales representatives (65+ per session) across 12 launch training programs.
  • ◆Led collaboration with Leukemia & Lymphoma Society on patient education and clinical trial enrollment.
  • ◆Trained newly-formed Oncology Field Medical Team on AML disease state.

Jul 2014 – May 2016

Ernest Mario School of Pharmacy, Rutgers

Adjunct Faculty

Piscataway, NJ

  • ◆Instructed semester-long Pharmacy Communications course for 34 students.
  • ◆Mentored student pharmacists rotating through Daiichi Sankyo Medical Affairs.
Core Competencies

Capabilities from medical strategy to the executive suite.

Corporate Strategy

Executive Leadership Partnership

Medical Strategy & Planning

KOL / Thought Leader Engagement

Advisory Board Design & Execution

Scientific Conference Management

Publication Planning

Medical Education & Training

Patient Advocacy & Engagement

Competitive Intelligence

Cross-functional Leadership

Regulatory & MLR Review

Education & Credentials

Foundations in pharmacy & clinical science.

Degree

Doctor of Pharmacy (Pharm.D.)

Ernest Mario School of Pharmacy, Rutgers University

2008 – 2014

Licensure

New Jersey Pharmacist License

Active, State of New Jersey

Let's Connect

Thoughtful collaboration.
Always welcome.

Open to conversations about corporate strategy, medical affairs, advisory opportunities, and partnership.

Nilomi.Shah.1@gmail.com LinkedIn

New York, NY